Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial NADH ubiquinone oxidoreductase, commonly known as Complex I, is the first and largest enzyme complex of the mitochondrial respiratory chain. It plays a central role in cellular energy metabolism by catalyzing electron transfer from NADH to ubiquinone (coenzyme Q10), coupled with proton translocation across the inner mitochondrial membrane. Defects or mutations in complex I subunits cause various inherited neuromuscular and metabolic disorders such as Leigh syndrome, Parkinson’s disease, ischemia/reperfusion injury after stroke or heart attack, among others. Dysfunctional complex I is also implicated in aging-related degenerative diseases due to increased ROS production.
Inhibition of electron transfer from NADH to ubiquinone
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial NADH Ubiquinone Oxidoreductase Complex I (Complex I).